Dataset on optimization and development of a point-of-care glucometer-based SARS-CoV-2 detection assay using aptamers

Naveen K Singh; Partha Ray; Aaron F Carlin; Sydney C Morgan; Celestine Magallanes; Louise C Laurent; Eliah S Aronoff-Spencer; Drew A Hall

doi:10.1016/j.dib.2021.107278

Dataset on optimization and development of a point-of-care glucometer-based SARS-CoV-2 detection assay using aptamers

Data Brief. 2021 Oct:38:107278. doi: 10.1016/j.dib.2021.107278. Epub 2021 Aug 12.

Authors

Naveen K Singh¹, Partha Ray², Aaron F Carlin³, Sydney C Morgan⁴, Celestine Magallanes⁴, Louise C Laurent⁴, Eliah S Aronoff-Spencer³, Drew A Hall^{1

5}

Affiliations

¹ Department of Electrical and Computer Engineering, University of California - San Diego, La Jolla, CA 92093, USA.
² Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California - San Diego Health, La Jolla, CA 92093, USA.
³ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California - San Diego, La Jolla, CA 92093, USA.
⁴ Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California - San Diego, La Jolla, CA 92093, USA.
⁵ Department of Bioengineering, University of California - San Diego, La Jolla, CA 92093, USA.

Abstract

We present supplementary data for the published article, "Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf glucometer" [1]. The assay described is designed to be performed at home or in a clinic without expensive instrumentation or professional training. SARS-CoV-2 is detected by an aptamer-based assay that targets the Nucleocapsid (N) or Spike (S) antigens. Binding of the N or S protein to their respective aptamer results in the competitive release of a complementary antisense-invertase enzyme complex. The released enzyme then catalyzes the conversion of sucrose to glucose that is measured by an off-the-shelf glucometer. The data presented here describe the optimization of the assay parameters and their contribution to developing this aptamer-based assay to detect SARS-CoV-2. The assay performance was checked in a standard buffer, contrived samples, and patient samples validated with well-established scientific methods. The resulting dataset can be used to further develop glucometer-based assays for diagnosing other communicable and non-communicable diseases.

Keywords: Aptamer; COVID-19; Enzyme; Glucometer; Point-of-care; Population screening; SARS-CoV-2.

Grants and funding

U54 EB027690/EB/NIBIB NIH HHS/United States